Država: Irska
Jezik: engleski
Izvor: HPRA (Health Products Regulatory Authority)
BUDESONIDE FORMOTEROL FUMATRATE DIHYDRATE
IPS Healthcare Limited
BUDESONIDE FORMOTEROL FUMATRATE DIHYDRATE
100/6 Mcg/Dose
Powder for Inhalation
Product subject to prescription which may be renewed (B)
Withdrawn
2013-03-28
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Symbicort Turbohaler 100 micrograms/6 micrograms/inhalation, inhalation powder 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose that leaves the mouthpiece) contains: budesonide 80 micrograms/inhalation and formoterol fumarate dihydrate 4.5 micrograms/inhalation. Symbicort Turbohaler 100 micrograms/6 micrograms/inhalation delivers the same amount of budesonide and formoterol as the corresponding Turbohaler monoproducts, i.e. budesonide 100 micrograms/inhalation (metered dose) and formoterol 6 micrograms/inhalation (metered dose) alternatively labelled as 4.5 micrograms/inhalation (delivered dose). Excipient: Lactose monohydrate 810 micrograms per dose. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Inhalation powder. _Product imported from The United Kingdom:_ White powder 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symbicort Turbohaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta 2 -agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting beta 2 - agonists. or patients already adequately controlled on both inhaled corticosteroids and long-acting beta 2 -agonists. NOTE: Symbicort Turbohaler (100 micrograms/6 micrograms/inhalation) is not appropriate in patients with severe asthma. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Route of administration: For inhalation use Symbicort Turbohaler is not intended for the initial management of asthma. The dosage of the components of Symbicort is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination products is initiated but also when th Pročitajte cijeli dokument